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Interventional clinical studies can provide the highest levels of evidence and generate signiﬁcant results
on speciﬁc investigational medicinal products or medical devices. In order to have powerful studies,
attain unquestionable results and make signiﬁcant discoveries, the number of patients enrolled must be
high. Therefore, multinational, randomised clinical trials are necessary. The multicentre, multinational
recruitment of subjects in investigator-initiated clinical trials (IICTs) increases their logistical burden,
justifying the need for speciﬁc infrastructures to ease implementation.
Herein, we provide for the ﬁrst time an overview of the facts and ﬁgures concerning IICTs, existing
infrastructures' capacity for interventional clinical research, and scientiﬁc performance of investigators in
a European country, Portugal. We aim to highlight the relevance and need for investing in European
infrastructures such as the European Clinical Research Infrastructure Network (ECRIN) for multinational
IICTs. A public, non-proﬁt organisation, ECRIN facilitates the conduct of multinational clinical trials in
Europe by coordinating scientiﬁc partners and their networks, and providing advice, management ser-
vices and tools to enhance collaboration. Currently in Portugal, few multinational randomised IICTs are
coordinated by national investigators. This is most likely due to the lack of human resources dedicated to
clinical trials in clinical research centres (CRCs) as well as the scarcity of professional academic clinical
trial units (CTUs) providing logistics and management services at non-proﬁt rates.
With the data shown, we expect to trigger the development of similar studies in other European
countries and stress the impact of government support for IICTs.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The European Clinical Research Infrastructure Network
(ECRIN) is one of the pan-European Biomedical and Medical
Sciences Research Infrastructures (BMS RIs) listed on the Euro-
pean Strategy Forum on Research Infrastructures (ESFRI) road-
map. It was awarded the status of European Research
Infrastructure Consortium (ERIC) by the European Commission in
2013 [1]. ECRIN is a non-proﬁt organisation that strives to
harmonise European clinical research; it provides services and
coordinates and manages high-quality, independent and fully
transparent multinational clinical trials, synergising the capa-
bilities of national clinical research infrastructures. Portugal hasMonteiro).
Inc. This is an open access article usigned the ECRIN statutes as a Member Country, together with
Germany, Spain, Italy, and France; country membership is paid
for by the national government. The Portuguese Clinical Research
Infrastructure Network (PtCRIN) is the scientiﬁc partner/national
hub of ECRIN in Portugal and the other members have homolo-
gous infrastructures. Scientiﬁc partners aim, on the one hand, to
provide support to national investigators seeking to interna-
tionalise clinical trials, and, on the other hand, to involve their
country in clinical trials initiated by investigators in other Eu-
ropean countries. Investigator-initiated clinical trials (IICTs) use a
patient-oriented approach and attempt to answer relevant
questions in clinical practice that may not otherwise be
addressed by companies [2]. IICTs may include studies for
possible treatment of rare diseases; paediatric trials with me-
dicinal products authorised for adults; comparative effectiveness
trials, enabling the comparison of diagnostic or therapeutic in-
terventions; and simulations of the development of surgicalnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Abbreviations
IICTs Investigator-Initiated Clinical Trials
2CA Clinical Academic Center e Braga [Centro Clínico
Academico de Braga]
AIBILI Association for Innovation and Biomedical Research
on Light and Image [Associaç~ao Para a Investigaç~ao
Biomedica e Inovaç~ao Em Luz e Imagem]
CEIC Portuguese National Ethical Commission [Comiss~ao
de Etica para a Investigaç~ao Clínica]
CHCB Centro Hospitalar da Cova da Beira
CHLC Centro Hospitalar Lisboa Central, E.P.E.
CHLN Centro Hospitalar de Lisboa Norte, E.P.E.
CHLO Centro Hospitalar de Lisboa Ocidental, E.P.E.
CHP Centro Hospitalar do Porto, E.P.E.
CHSJ Centro Hospitalar S~ao Jo~ao, E.P.E.
CHUC Centro Hospitalar da Universidade de Coimbra
CIC-CAML Centro de Investigaç~ao Clínica - Centro Academico
de Medicina de Lisboa
FMUP Medical School from Oporto University [Faculdade
de Medicina da Universidade do Porto];
FTE Full Time Equivalent
IPO-L Oncology Institute of Lisbon [Instituto Portugue^s de
Oncologia de Lisboa]
HFF Hospital Prof. Doutor Fernando da Fonseca
IPO-P Oncology Institute of OPorto [Instituto Portugue^s de
Oncologia do Porto]
NMS Nova Medical School [Faculdade de Cie^ncias
Medicas], Universidade Nova de Lisboa
UC University of Coimbra [Universidade de Coimbra]
UM University of Minho [Universidade do Minho]
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IICTs provide the robust evidence to enable policy makers to
make informed and sustainable policy decisions on public health.
Investigators leading such trials generally obtain ﬁnancial sup-
port from European or national funds, patient associations,
other non-proﬁt organisations, or competitive grants from the
pharmaceutical industry. A limitation is that these funds are not
adapted to the timeframe for patient recruitment and follow-up
of chronic diseases, and generally do not allow for subcontracting
with for-proﬁt Clinical Research Organisations (CROs). When
the logistical support for submission and management of an IICT
is lacking, the quality of the research is impaired and in-
vestigators face an enormous workload, usually hampering the
success of the investigation. Additionally, to extract evidence
from an IICT, it is necessary to have a powerful sample, which, in
most cases, is only possible to attain in multinational trials.
This presents an added challenge without industry sponsorship,
as there are different requirements in different European coun-
tries. Barriers to multinational IICTs could be reduced by
simplifying, centralising, and harmonising application and
governance procedures [3,4], and by linking national in-
frastructures through a distributed network such as ECRIN. For
this purpose, the continuous funding and commitment of gov-
ernments is crucial.
The present study aims to analyse the current status of IICTs in
one ECRIN Member Country, i.e., Portugal. Results were gathered
from members of the scientiﬁc partner (PtCRIN). For the ﬁrst time,
we provide quantitative indicators on IICTs that might be useful for
restructuring priorities towards strengthening competitiveness in
different European countries.2. Methods
2.1. PtCRIN members
PtCRIN includes eight healthcare units (Centro Hospitalar da
Cova da Beira e CHCB; Centro Hospitalar Lisboa Central e CHLC;
Centro Hospitalar de Lisboa Ocidental e CHLO; Centro Hospitalar
do Porto e CHP; Centro Hospitalar S~ao Jo~ao e CHSJ; HFF- Hospital
Prof. Doutor Fernando da Fonseca; Instituto Portugue^s de Oncologia
de Lisboae IPO-L; Instituto Portugue^s de Oncologia do Portoe IPO-
P), one non-proﬁt clinical research organisation (Association for
Innovation and Biomedical Research on Light, AIBILI), and ﬁve ac-
ademic medical centres or universities (Centro Clínico Academico
de Braga e 2CA-Braga; Centro de Investigaç~ao Clínica - Centro
Academico de Medicina de Lisboa e CIC-CAML; Faculdade de
Medicina da Universidade do Porto e FMUP; Nova Medical School,
Universidade Nova de Lisboa e NMS; University of Coimbra e UC).
The selection of PtCRIN members was determined based on a
survey sent in 2013 to all health organisations in Portugal with
ongoing clinical trials, aiming to assess capacity for clinical
research. Organisations with the highest number of clinical trials,
afﬁliated with medical schools, and motivated to improve their
clinical research units and to internationalise their performance in
clinical researchwere retained. Later, end 2014, another survey was
sent to all 14 PtCRIN members to receive updated information on
their capacity in terms of clinical trials and respective facilities.
From April to July 2015, a meeting was held between the repre-
sentatives of each member institution and the PtCRIN core team;
this was the opportunity to conﬁrm member expectations
regarding PtCRIN, as well as their capacity, facilities, employee data,
and number of IICTs.
Under the ECRIN framework, PtCRIN members are divided ac-
cording to the following categories [5]:
a) Clinical Research Centres (CRCs), health care-based organisa-
tions devoted to clinical research, with designated beds,
equipment, medical and study-nurse staff, allowing enrolment
and investigation of patients in the early phases of drug trials
and in non-therapeutic studies (CHP, CHSJ, CHLC, HFF, CHLO,
CIC-CAML, IPO-L, IPO-P, CHCB, 2CA-Braga, AIBILI).
b) Clinical Trial Units (CTUs) to manage clinical trials, namely
randomised clinical trials (phase II-IV), prognostic, diagnostic
studies, andmeta-analyses, dealing with the design of the study,
its organisation, logistics, centre selection, data management,
monitoring, data analysis, pharmacovigilance and reporting
(NMS, AIBILI, and to be developed by UC and FMUP).2.2. Number of clinical trials in European countries
Clinical trial data for this study were obtained from the Euro-
pean Clinical Trials Database (EudraCT, www.clinicaltrialsregister.
eu) using the search terms/status “name of the country” and
“commercial/non-commercial”; the search was limited to the
period prior to 31 July 2015. The number of citizens was obtained
from Eurostat (http://ec.europa.eu/eurostat) in July 2015.
2.3. Number of and details on clinical trials initiated by
investigators in Portugal
Data were obtained from the EudraCT database in July 2015
using the search terms “Portugal” and “non-commercial”. Only
ongoing clinical trials in Portugal that were clearly initiated by in-
vestigators were considered. A total of 51 clinical trials were found
(S.I.1). The distribution of ongoing clinical trials in each institution
C. Madeira et al. / Contemporary Clinical Trials Communications 4 (2016) 141e148 143was kindly provided by the national Ethical Commission (Comiss~ao
de Etica para a Investigaç~ao Clínica, CEIC) for registries submitted
between 2011 and still ongoing as of July 2015.
2.4. Number of and details on investigator-initiated interventional
studies in Portugal
Data were obtained from the clinicaltrials.gov database in July
2015 using the terms “Portugal”, “device” or “procedure”. Only
ongoing, interventional studies with known status were consid-
ered. Of the 53 studies screened, only 19 did not have industry
sponsorship (S.I.2).
2.5. Number of publications about clinical research in Portugal
All studies published in English or Portuguese addressing
interventional studies in Portugal were identiﬁed. This was ach-
ieved by searching the PubMed MEDLINE database, ﬁrst using the
term “Randomi*” in the title, and “Portugal” in the address from
2010 to August 2015, and then using the name of the health centre,
and “Portugal” in the address from January 2014 until August 2015.
With the ﬁrst search, 209 publications were found and
screened; only 48 focused on randomised interventional studies
with drugs or medical devices (S.I.3) and were considered for this
publication. Feedback to validate this information was requested to
all PtCRIN members; responses were provided from 2CA-Braga,
AIBILI, CHCB, CHLC, CHP, CHSJ, IPO-L and IPO-P.
After registering data from the latter search, a table was sent to
each PtCRIN member to conﬁrm the number and details of the
publications and to request missing information. Responses were
provided from 2CA-Braga, AIBILI, CHCB, CHLC, CHP, IPO-L and IPO-P.
A total of 1540 publications were screened.
3. Results
3.1. Clinical trials in Europe: commercial vs. investigator-initiated
clinical trials
European countries such as the United Kingdom (UK), Italy,
Germany and Spain were able to attract industry sponsorship for
clinical trials (>4000 clinical trials registered until July 2015),
enabling access to innovative medicines for patients and stimu-
lating high-quality clinical research (Fig. 1A). In Europe these
countries also have the highest number of IICTs (>1500), repre-
senting only 20e35% of the total number of registered trials in each
country (Fig. 1A, S.I.4). In Portugal, only 8% of all registered clinical
trials are initiated by investigators without industry sponsorship,
while the European average is 17% (Fig. 1A). Indeed, Portugal is
below the European average in regards to both types of clinical
trials. When considering the size of the population in each country,
Denmark, Austria and Finland are the ones with the highest num-
ber of clinical trials per one million citizens (Fig. 1B).
3.2. Investigator-initiated interventional studies in PtCRIN member
institutions
From the 917 interventional studies (drugs, medical devices and
surgical procedures) ongoing in Portugal, 70 are non-commercial,
corresponding to 8% of the total number of clinical trials (Fig. 2A).
Interestingly, only 13% (n¼ 9) of these investigator-initiated studies
are non-randomised (Fig. 2B) and most studies involve the use of
chemical drugs (Fig. 2C) in Phase III (Fig. 2D). Around 64% (n ¼ 45)
of IICTs ongoing in Portugal are multinational (Fig. 2E), which
shows the openness of Portuguese investigators to embrace inter-
national studies. Additionally, investigators from CHLN, AIBILI andCHSJ are sponsors of international studies (S.I.1).
As expected, most of the clinical trials currently being conducted
by PtCRIN members are industry-initiated. At oncology institutes,
IPO-P and IPO-L, and CHLO, more than 10% of the total number of
clinical trials are initiated by investigators (Fig. 3A). It is noteworthy
that the percentage of IICTs at IPO-L, around 30%, is similar to that
observed in European countries with the highest number of IICTs
(Fig. 1B). Another relevant fact is that 64% of the total number of
IICTs in Portugal are multinational and the majority are focused on
cancer, followed by heart and joint diseases (Fig. 3B).
3.3. Human resources allocated to clinical trials in PtCRIN members
At the moment, PtCRIN is a consortium of institutions and is
focused on developing two major activities: i) establishing and
developing a coherent national network of CTUs compliant with
European and national guidelines and regulations; and ii) devel-
oping national CRCs with the minimum requirements needed to
perform clinical trials compliant with national and European reg-
ulations/guidelines. Currently, PtCRIN has two CTUs providing
external services at non-proﬁt rates for the management of clinical
trials, including those that are multinational.
As shown in Fig. 4, large hospital centres (number of
beds > 1000) (CHLO, CHLC, CHP, CHSJ, CHCB, 2CA) and oncology
institutes (IPO-L, IPO-P), public non-proﬁt organisations, are
currently struggling with the lack of human resources exclusively
allocated to clinical trials. Even IPOs, with a higher percentage of
IICTs and huge potential for starting IICTs, have relatively few
dedicated resources (S.I.5). Nonetheless, several hospitals in
Portugal have already begun centralising clinical research unit
procedures, quality management systems and publications in peer-
reviewed scientiﬁc journals.
3.4. PtCRIN member publications in clinical research
The results gathered in this section include all types of publi-
cations, namely: randomised studies, systematic reviews andmeta-
analyses, non-randomised interventional and observational
studies, and case reports. From January 2014 until August 2015,
PtCRIN members collectively published around 2,5 of such papers
every day. Fig. 5 includes a summary of information collected from
1540 publications by PtCRIN members published in this timeframe.
Based on the information amassed from the last 20 months and
depicted in Fig. 5, it is clear that most of the studies are accom-
plished solely by national teams and published in journals with an
impact factor (i.e., index that reﬂects the number of citations) be-
tween 1 and 4. The physicians from the therapeutic areas of
oncology, cardiology, neurology and gastroenterology have higher
publication rates when compared to other areas of medical
expertise. In Fig. 5D, it is possible to observe that high numbers of
case reports and observational studies do not correlate with a high
impact factor of the journals. On the other hand, randomised
clinical studies, systematic reviews and meta-analyses, as well as
studies focused on genetic analysis are generally published in
journals with a higher impact factor when compared to other types
of studies. In Portugal, publications with impact factors higher than
10 correspond to 4% of the total number of publications.
Randomised studies are generally published in high-impact
scientiﬁc journals and, given the complexity and dimension of
the study, which is mandatory to achieve a meaningful result, they
are frequently sponsored by the industry. In Portugal, most of the
published randomised studies used chemical-based medicines
(Fig. 6A) and were multinational (Fig. 6B). The therapeutic areas
targeted in the highest impact factor journals are: cancer, heart
disease and urology (S.I.3). This is an excellent indicator that if
Fig. 1. Clinical trials registered in Europe. A) Number of clinical trials in each country. Grey shading refers to current ECRIN Member Countries; B) Number of clinical trials per one
million citizens. To access more data please see S.I.4.
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dustry studies receive, they would also be able to accomplish
randomised, complex clinical trials and publish their ﬁndings in
high-impact scientiﬁc journals.
4. Discussion
Randomised screening trials are bothersome. It takes ages to come
to an answer, and these need to be large e scale projects to be able
to answer the questions. [But …] there is no second-best option.
H.J. de Koning, Annals of Oncology, 2003
To the best of our knowledge, this is the ﬁrst study speciﬁcally
addressing the performance of a country in terms of investigator-
initiated clinical studies. Comparison with other European coun-
tries is difﬁcult because indicators of scientiﬁc performance, human
resources allocated to clinical trials or therapeutic areas of non-
commercial clinical trials are not commonly explored in available
publications. We intend to highlight the relevance of using per-
formance indicators in clinical research as well as to underline the
advantages of countrymembership in ECRIN as ameans to facilitate
multinational IICTs.
Throughout the last decade, the adoption of directive 2001/20/
EC by each European country led to a clear decrease in the number
of academic trials [2]. Indeed, investigators carrying out a study
with a well-established drug that is commonly used in daily prac-
tice have to comply with the same rigorous regulations as large
pharmaceutical companies investigating the potential of a novel
therapy; this applies even though, in most cases, the risk for the
trial participants does not always justify the ﬁnancial and regula-
tory burdens imposed [6]. Besides regulatory fragmentation in
different countries, there are other bottlenecks in the conduct ofmultinational studies including informed consent, ethical review,
data monitoring, adverse events, insurance, costs, funding, training
and language [7]. In Europe, the number of applications to under-
take clinical trials fell from 5000 to 3800 between 2007 and 2011,
and the administrative costs for academic trials rose by 98% [8]. On
the other hand, in Denmark an opposite trend was observed; this
can likely be explained by the implementation in 1999 of good
clinical practice units in universities and hospitals, with public
funds, to support the implementation andmanagement of IICTs [9].
Denmark is currently the country with highest number of clinical
trials per one million citizens (Fig. 1B).
In Germany, in a successful attempt to circumvent the aforesaid
problems, a former working group of the Coordinating Centres for
Clinical Trials was transformed into a consortium supported by the
government e the KKS Network [10,6]. From 1999 to 2015, the KKS
Network received 77 million euros from the German government.
The existence of this infrastructure of clinical trial units (CTUs)
might be responsible for the highest values of clinical trials per
million citizens, including IICTs when compared to other European
countries (Fig. 1B). The French government provided total funding
of 18million euros for a period of eight years to create FCRIN (www.
fcrin.org), which is the French scientiﬁc partner of ECRIN. In France,
investigators have access to several types of training, including
H2020 training for clinical trials; they are supported by a strong
network of CTUs and CRCs; and they are extremely competitive in
attracting European funds. In the UK, a registration process was
developed to ensure that CTUs meet regulatory and quality stan-
dards (www.nets.nihr.ac.uk/programmes/ctu). With this multi-
stage, government-supported activity, the number of cancer pa-
tients enrolled in clinical trials increased by 20% [11]. Besides
providing operational support to manage interventional studies
initiated by investigators or thematic networks, these CTUs can also
contribute to establishing a harmonised quality management
Fig. 2. ePercentage of ongoing, interventional clinical studies (IICT) in Portugal (Total number ¼ 917). A)Type of sponsor; B) Design of the non-commercial study that includes
IICTs on medical devices and surgical procedures; C) Type of health technology of non-commercial clinical studies; D) Development phase of non-commercial medicine; E) Location
of non-commercial clinical studies.
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provide training in good clinical practices (GCPs).
Based on these examples, the involvement of local and distrib-
uted (i.e., spanning across different countries) infrastructures to
support investigators throughout the entire process of a clinical
study seems crucial to fulﬁl the requirements and achieve the ob-
jectives in IICTs. As such, the involvement of ECRIN, a distributed
network, and PtCRIN, a national network encompassing multiple
Portuguese partners, is a step in the right direction.
Currently in Portugal, the percentage of IICTs is still below
average when compared to all countries in the European Union
(Fig. 1). The reasons are mainly related to: a) the low number of
national programmes for non-commercial clinical research funding
(the few programmes that are launched are insufﬁcient for spon-
soring powerful interventional clinical studies); b) limited funding
for PtCRIN core activities; c) insufﬁcient human resources,
including physicians, fully dedicated to clinical trials in health
centres; and d) lack of local infrastructures such as CTUs to supportinvestigators in non-commercial trials.
Most ongoing IICTs in Portugal are randomised and are spon-
sored by non-for-proﬁt organisations with national and/or Euro-
pean funds. Additionally, around 64% of the IICT in Portugal are
multinational in agreement with the results recently shown by
others [12]. This number shows that the ﬁrst steps towards
increasing the number and impact of these clinical trials have been
taken. Oncology institutions have a higher percentage of IICTs
when compared to other national health organisations (Fig. 3A).
Nevertheless, they are struggling with the need for human re-
sources fully dedicated to clinical trial operations (Fig. 4). The main
consequence of this is a slow recruitment of patients and lower
capacity for accepting new clinical trials, even from the industry.
Indeed, the feasibility of randomised trials often depends on suc-
cessful patient recruitment [13]. A recent study (SAT-EU) system-
atically investigated factors impacting trial site attractiveness
across Europe; it found that investigator-dependent factors, such as
recruitment speed and ease of approval, dominate trial site
Fig. 3. Investigator-initiated clinical trials ongoing in PtCRIN members. A) Percentage of IICTs per Clinical Research Centre (CRC) (yellow bar) with total number of clinical trials
(black number); B) Medical conditions of interventional investigator-initiated studies (drugs, medical devices and surgical procedures) ongoing in PtCRIN's CRCs. (For interpretation
of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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mentioned KKS Network in Germany is one successful example of
an organisation that has been able to increase recruitment efﬁcacy
[15].
In line with what is observed in other countries, oncology is the
largest therapeutic area in IICTs and most IICTs in this ﬁeld are
multinational, although few sites are generally considered toFig. 4. e Comparison of total number of clinical trials and number of non-physician sta
not available for CIC-CAML (CHLN) and HFF. FTE- Full Time Equivalent (S.I.5).recruit patients (S.I.1). Additionally, a small number of IICTs have a
national sponsor, clearly reﬂecting the lack of capacity of organi-
sations to incite investigators to lead multinational studies, espe-
cially those funded by European initiatives.
Despite the high percentage of randomised trials when
compared to the total IICTs in Portugal (Fig. 2B, E), the former
represents only around 2% of all published papers since 2014ff working full time in clinical research at PtCRIN member CRCs. Staff numbers were
Fig. 5. Scientiﬁc papers of PtCRIN members published in peer-reviewed journals cited in PubMed between January 2014 and August 2015 (in percentage; total ¼ 1540). A) Type
of teams involved in published papers involving international cooperation; B) Impact factor (IF) range for journals in which scientiﬁc papers were published; C) Percentage of papers
published with work regarding each area of medical expertise; D) Overlay of the graph displaying the number of publications (%) (red) using each study type with the graph
showing the average IF (green) of the journals where the paper was published - calculated as the ratio between the accumulated IF (Accum. IF) and the number of papers published
for each study type. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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lished in peer-reviewed scientiﬁc papers or presented in confer-
ences, which are increasingly valued as a means to attract further
funding and to boost an investigator's career. Additionally, since
October 2013, theWorldMedical Association (WMA) Declaration of
Helsinki included the mandatory requirement of making publicly
available the results of research on human subjects, including
negative results independently of the type of sponsor [16].
The majority of our publications in clinical research rely on the
description of case reports (30%) and observational studies (25%)
with an average impact factor of 2.5 and 3, respectively (Fig. 5D).
Conversely, randomised studies are published in journals with an
average impact factor of 7. The design, implementation, conduct
and results analysis of these studies should be performed in a
structured way to increase the power of the evidence of the results
[17]. Therefore, the existence of national and international clinicalFig. 6. Randomised clinical studies accomplished in Portugal and published from 2010 t
the published studies; B) Number of investigator- and industry-initiated clinical trials and m
(multinational).research infrastructures with experts to support physicians in these
clinical trials is decisive.
In Europe, countries with these infrastructures, such as Ger-
many, France or the UK have shown a rise in the number and
quality of clinical trials. ECRIN scientiﬁc partners such as PtCRIN
have a key role in this process; they bring together national in-
frastructures in clinical research, linking national investigators to a
European infrastructure (i.e., ECRIN) of patient recruitment sites
and CTUs for managing clinical trials locally. Although the assess-
ment of the impact of being integrated in this consortium will be
evident in the near future, current progress probably would not
have been achieved without the involvement of ECRIN.
Overall, this work attempts to create a precedent in European
countries to evaluate the added value of ECRIN and to measure the
impact of investigator-initiated clinical research in the healthcare
sector. It suggests some indicators that might be considered; othero July 2015 (Total number ¼ 48). A) Percentage of different health technologies used in
edical device studies carried out in Portugal alone (national) and in several countries
C. Madeira et al. / Contemporary Clinical Trials Communications 4 (2016) 141e148148quantitative indicators such as recruitment efﬁcacy and speed are
expected to be included in future analysis.5. Conclusions
The ﬁrst steps towards high-quality IICTs in Portugal have been
taken through membership in ECRIN. Although PtCRIN's scientiﬁc
output is far from the desired result, we foresee that being a sci-
entiﬁc partner of ECRIN will increase performance in the next few
years. Our results might trigger the development of similar studies
in other European countries seeking to conﬁrm ECRIN's added
value and produce accurate comparative studies in IICTs. The
engagement of national governments in building the capacity of
infrastructures dedicated to managing interventional IICTs at non-
proﬁt rates is, in our view, crucial to achieve high-quality evidence
in health technologies to improve health care and the sustainability
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